Skip to main content
Premium Trial:

Request an Annual Quote

New Products: A Mass Spec-Based Thyroglobulin Test from Quest and More

Premium

Quest Diagnostics has introduced its Thyroglobulin Post-treatment Monitoring Test for monitoring recurrence of thyroid cancer following surgery.

The product is the first clinical test to use mass spectrometry to measure Tg, the company said, and is intended for use in samples where anti-Tg autoantibody production precludes use of conventional immunoassays.


Phenomenex this week released its new Yarra line of aqueous size exclusion chromatography columns for biomolecule analysis.

The columns come in three phases with 3-micron particles and are designed for separations of small to large proteins and peptides as well as biopharmaceuticals.


Enzo Life Sciences has released its new [pThr202/Tyr204]Erk ½ ELISA kit, which its says allows for detection of as little as 2.67 pg/ml of phosphorylated ERK1/2 and can process up to 40 samples in duplicate in three hours.


Everest Biotech is offering custom goat polyclonal antibodies for $300 for its collaborators. According to the company it will take on as many as 20 custom antibody projects per month.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.